SPPL3 Activators
SPPL3 include a range of gamma-secretase inhibitors, such as DAPT, LY-411575, L-685,458, Semagacestat, Begacestat, and Avagacestat. These inhibitors work by blocking the cleavage of proteins typically processed by gamma-secretase, which in turn increases the availability of these substrates for SPPL3. By preventing these proteins from being processed by gamma-secretase, the inhibitors cause a substrate buildup that SPPL3 can then act upon. Although each of these chemicals has a unique structure and may vary in potency and selectivity, their fundamental impact on the substrate availability for SPPL3 is consistent. As gamma-secretase is inhibited, SPPL3 encounters an expanded pool of substrates, allowing for its activation and subsequent increase in proteolytic activity. This action facilitates the cleavage of proteins within the cell membrane, a process essential for the function of SPPL3.
gamma-secretase inhibitors, several statins such as Atorvastatin, Simvastatin, Mevastatin, Rosuvastatin, Pitavastatin, and Pravastatin can also play a role in the activation of SPPL3. These statins primarily inhibit HMG-CoA reductase, an enzyme crucial for cholesterol synthesis. Reduced cholesterol synthesis leads to changes in the cell membrane's lipid composition and fluidity. These alterations can affect the environment in which SPPL3 operates, thereby increasing the functional activity of SPPL3. The statins' influence on cholesterol metabolism can modify the availability and the processing efficiency of SPPL3's substrates within the membrane. By altering the cellular lipid milieu, statins contribute to the optimal conditions required for SPPL3 to cleave its substrates, which is a central aspect of its role in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor which, by inhibiting the cleavage of substrates other than SPPL3, may increase the availability of substrates for SPPL3, thus leading to its increased functional activity as it processes alternative substrates. | ||||||
Dibenzazepine (Deshydroxy LY 411575) | 209984-56-5 | sc-207554 sc-207554A | 2 mg 5 mg | $235.00 $260.00 | 4 | |
LY-411575, another gamma-secretase inhibitor, similarly to DAPT, could increase substrate availability for SPPL3 and thereby enhance its proteolytic activity by preventing substrates from being processed by gamma-secretase. | ||||||
L-685,458 | 292632-98-5 | sc-204042 sc-204042A | 1 mg 5 mg | $337.00 $1000.00 | 4 | |
L-685,458 is a highly selective gamma-secretase inhibitor and could indirectly activate SPPL3 by causing a buildup of its substrates that are not processed by gamma-secretase, leading to increased functional activation of SPPL3. | ||||||
Semagacestat | 425386-60-3 | sc-364614 sc-364614A | 10 mg 50 mg | $350.00 $1200.00 | 1 | |
Semagacestat, although primarily developed for Alzheimer's disease, acts as a gamma-secretase inhibitor which may lead to an accumulation of SPPL3 substrates, subsequently enhancing the functional activation of SPPL3. | ||||||
BMS-708163 | 1146699-66-2 | sc-364444 sc-364444A | 10 mg 50 mg | $480.00 $1455.00 | 1 | |
As a gamma-secretase inhibitor, Begacestat may potentiate the activity of SPPL3 indirectly by increasing the pool of substrates available for SPPL3 to cleave due to the inhibition of their processing by gamma-secretase. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin, a statin that inhibits HMG-CoA reductase, could lead to altered cholesterol metabolism and membrane composition, which may favor the functional activation of SPPL3 due to its role in the intramembrane cleaving of proteins. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin, another HMG-CoA reductase inhibitor, might influence membrane lipid composition, potentially altering the environment in which SPPL3 operates, leading to its functional activation due to changes in substrate accessibility. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $77.00 $179.00 | 18 | |
Mevastatin, a natural statin, by modulating cholesterol biosynthesis, could affect the membrane dynamics and thereby indirectly activate the functional activity of SPPL3 by affecting the distribution and availability of its substrates. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin, by influencing cholesterol synthesis, could alter membrane properties, which may in turn activate SPPL3 by changing substrate availability or membrane-associated dynamics important for SPPL3 function. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $69.00 $162.00 $787.00 | 2 | |
Pravastatin, another statin affecting cholesterol metabolism, might alter the lipid composition of membranes, potentially leading to an increase in functional activation of SPPL3 through enhanced substrate accessibility. | ||||||